Short course of clarithromycin in an immunocompetent patient with BCG-induced regional complications.
Bacillus Calmette Guerin (BCG) has been used to vaccinate against tuberculosis since 1921. Persistant skin and lymph node lesions yielding Mycobacterium bovis are a rare complication for which there is not standardized treatment. We report an 11 month old child with a progressive cutaneous nodule and lymphadenopathy after BCG vaccination. These rapidly cleared with administration of clarithromycin.
Torres-Rojas
J R
JR
Instituto de Medicina Tropical, Universidad Central de Venezuela, Caracas, Venezuela.
Rondón-Lugo
A
A
Vidal
Rosa
R
D000284:Administration, Oral; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007121:Immunocompetence; D007223:Infant; D008206:Lymphatic Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D009163:Mycobacterium bovis / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D014376:Tuberculosis / Q000517:prevention & control
D001500:BCG Vaccine; D017291:Clarithromycin